Immunome develops targeted cancer therapies, with a focus on antibody drug conjugates and an investigational treatment for desmoid tumors. It last closed at $17.18 on Nov 17, down 2.44% on the day. The average 12-month price target from 3 analysts is $28.33 (+64.9% from the last close), with a high of $32.00 and a low of $23.00. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $1.4M, the largest $1.4M.
Each firm's latest rating on IMNM in the past 90 days
Average 12-month target
$28.33
▲ 64.9% upside
Based on 3 analysts who set a price target on IMNM in the past 90 days. The average target is $28.33, with a high of $32.00 and a low of $23.00, compared with the last close of $17.18.
Low $23.00Avg $28.33High $32.00
Blue marker: last close $17.18
Highest target$32.00
Average target$28.33
Lowest target$23.00
Latest rating changes
StifelTarget lowered
Nov 10Hold$24 → $23
Piper SandlerMaintained
Nov 10Buy$30
StifelInitiated
Oct 1Hold$24
Alliance Global PartnersInitiated
Sep 21Buy$32
Truist SecuritiesTarget raised
Aug 12Buy$37 → $38
Date
Firm
Action
Rating
Price target
Nov 10
Stifel
Target lowered
Hold
$24 → $23
Nov 10
Piper Sandler
Maintained
Buy
$30
Oct 1
Stifel
Initiated
Hold
$24
Sep 21
Alliance Global Partners
Initiated
Buy
$32
Aug 12
Truist Securities
Target raised
Buy
$37 → $38
Loading…
Technical Analysis
IMNM · as of the Nov 17 close · updated after every close
Downtrend
The stock is 8% below its 20 day and 18% below its 50 day average. It is 29% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot S1 at $16.59, and the nearest resistance the Pivot at $17.37.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.4%/day
Key levels
$30.0652 week high+75.0%
$22.65100 day average+31.8%
$22.13200 day average+28.8%
$20.2850 day average+18.0%
$18.5820 day average+8.1%
$18.44Swing high (Oct 21)+7.3%
$17.97Pivot R1+4.6%
$17.37Pivot+1.1%
$17.18Last close
$16.59Pivot S1−3.4%
$16.4152 week low−4.5%
$16.41Swing low (Oct 16)−4.5%
Indicators
RSI (14)
38.62
Weak, oversold below 30
Neutral
MACD
-0.52
Above its signal line
Bullish
Stochastic
13.4
Near the bottom of its range
Oversold
ADX (14)
21.4
Weak trend
Williams %R
-93.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-160.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−15.4%
Change over 10 sessions
Bearish
ATR (14)
$1.27
Typical daily range, 7.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityNormal, 15.8%/day
Key levels
$30.0652 week high+75.0%
$22.65100 day average+31.8%
$22.13200 day average+28.8%
$20.2850 day average+18.0%
$18.5820 day average+8.1%
$18.44Swing high (Oct 21)+7.3%
$17.97Pivot R1+4.6%
$17.37Pivot+1.1%
$17.18Last close
$16.59Pivot S1−3.4%
$16.4152 week low−4.5%
$16.41Swing low (Oct 16)−4.5%
Indicators
RSI (14)
37.91
Weak, oversold below 30
Neutral
MACD
-1.09
Below its signal line
Bearish
Stochastic
13.3
Near the bottom of its range
Oversold
ADX (14)
20.5
Weak trend
Williams %R
-94.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-108.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−30.4%
Change over 10 sessions
Bearish
ATR (14)
$2.71
Typical daily range, 15.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200–
What happened before, for IMNM
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IMNM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow IMNM usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IMNM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMNM is in one of them and how their past IMNM trades turned out.
Immunome is a biotechnology company based in Bothell, Washington, that develops targeted cancer treatments. Its main focus is antibody drug conjugates, a type of therapy that carries cancer fighting drugs to tumor cells, along with other oncology therapies. Its lead candidate, varegacestat, is an investigational oral treatment for desmoid tumors, a rare connective tissue tumor. The company aims to serve cancer patients and the doctors who treat them.